Anzeige
Mehr »
Sonntag, 01.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P16 | ISIN: SE0022419784 | Ticker-Symbol: 61L0
Frankfurt
27.02.26 | 16:30
18,220 Euro
+11,44 % +1,870
1-Jahres-Chart
SECTRA AB Chart 1 Jahr
5-Tage-Chart
SECTRA AB 5-Tage-Chart
RealtimeGeldBriefZeit
17,70018,40028.02.
PR Newswire
399 Leser
Artikel bewerten:
(2)

Sectra begins implementation of its first digital pathology project in Japan, aiming to improve cancer diagnostics and decrease time to treatment

LINKÖPING, Sweden, Jan. 7, 2026 /PRNewswire/ -- International medical technology and cybersecurity company Sectra (STO: SECT B), in collaboration with distribution partner Matsunami Glass has commenced the implementation phase of its first digital pathology project in Japan. This milestone marks Sectra's entry into the Japanese digital pathology market and highlights the potential of its technology to advance diagnostic capabilities and support the country's evolving healthcare needs.

"Collaborating with Kameda Medical Center for Sectra's first digital pathology project in Japan is a significant milestone for us. We are honored to receive an order from such a respected institution and to work closely with Professor Fukuoka. This demonstrates our commitment to being a trusted partner for Japanese healthcare providers, supporting their adoption of digital pathology and enabling more efficient diagnostics to improve patient care," says Torbjörn Kronander, President and CEO of Sectra AB.

The implementation of Sectra's digital pathology module at Kameda Medical Center follows a contract signed in the second quarter of Sectra's 2025/2026 fiscal year. The contract was sold by Sectra's distribution partner of digital pathology in Japan, Matsunami Glass.

Sectra's digital pathology solution will allow the pathologists at Kameda Medical Center to enhance review and collaboration around cases as well as benefit from tightly integrated AI tools. The digital workflow provides instant and, when needed, remote access to digital images of tissue samples instead of relying on physical glass slides reviewed in microscopes.

"After nearly a decade of successful operation as a fully digital pathology laboratory, we are entering a new phase and have made a strategic decision to transition from a scanner-restricted workflow to a comprehensive digital pathology module. To support this evolution, we are partnering with Sectra, whose platform offers robust compatibility, interoperability, and data security," says Professor Junya Fukuoka, Chair of the Department of Pathology at Kameda Medical Center.

About Kameda Medical Center

Recognized for its broad range of clinical services, multidisciplinary approach, and commitment to patient-centered care, Kameda Medical Center is one of Japan's largest healthcare providers. It is ranked among the top three hospitals in Japan in Newsweek's World's Best Hospitals 2025. The organization comprises Kameda General Hospital, Kameda Clinic, and additional clinics and rehabilitation units within the Kameda Group, altogether providing care for a large population in southern Chiba and the Tokyo metropolitan area.

About Sectra's enterprise imaging solution

The digital pathology module is part of Sectra's enterprise imaging solution that provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise without acquiring a new back end. Visit Sectra's website to read more about Sectra and why it's top-ranked in 'Best in KLAS'.

For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/sectra/r/sectra-begins-implementation-of-its-first-digital-pathology-project-in-japan--aiming-to-improve-canc,c4283885

The following files are available for download:

https://news.cision.com/sectra/i/sectras-digital-pathology-module,c3496956

Sectras digital pathology module

Cision View original content:https://www.prnewswire.co.uk/news-releases/sectra-begins-implementation-of-its-first-digital-pathology-project-in-japan-aiming-to-improve-cancer-diagnostics-and-decrease-time-to-treatment-302654948.html

© 2026 PR Newswire
Tech-Aktien schwanken – 3 Versorger mit Rückenwind
Die Stimmung an den Märkten hat sich grundlegend gedreht. Während Tech- und KI-Werte zunehmend mit Volatilität und Bewertungsrisiken kämpfen, erleben klassische Versorger ein unerwartetes Comeback. Laut IEA und EIA steigt der globale Strombedarf strukturell weiter, nicht nur wegen E-Mobilität und Wärmepumpen, sondern vor allem durch energiehungrige KI-Rechenzentren. Energie wird damit zur zentralen Infrastruktur des digitalen Zeitalters.

Gleichzeitig rücken in unsicheren Marktphasen stabile Cashflows, solide Bilanzen und regulierte Renditen wieder stärker in den Fokus. Genau hier spielen Versorger ihre Stärken aus: berechenbare Erträge, robuste Nachfrage und hohe Dividenden – Qualitäten, die vielen Wachstumswerten aktuell fehlen.

Nach Jahren im Schatten der Tech-Rallye steigt nun das Interesse an Unternehmen, die Stabilität mit langfristigen Wachstumsthemen wie Netzausbau, Dekarbonisierung und erneuerbaren Energien verbinden.

Im aktuellen Spezialreport stellen wir drei Versorger vor, die defensive Stärke mit attraktivem Potenzial kombinieren.

Jetzt den kostenlosen Report sichern – bevor die nächste Versorgerwelle Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.